Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which include a highly anticipated oral pill.
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...
4don MSN
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
Investor's Business Daily on MSN8d
Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk BeatViking Therapeutics reported promising early results for its experimental obesity pill, with increased weight loss at higher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback